Harold Dauerman, MD
Cardiovascular Disease · Burlington, VTNPI 1760494272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $183,265 of the $248,201 with a category attached, or 73.8%. Medtronic accounts for 82.1% of it on its own, with 4 other manufacturers making up the rest. Among cardiovascular disease clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $1069.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$204K
- Boston Scientific$25K
- Edwards Lifesciences$16K
- Abiomed$3K
- Abbott$150
Across 265 payments — averaging $4395.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$774K
- Medtronic$381K
- Abbott$5K
- Bayer$5K
What the payments were for
- Consulting fees$48,05619%
- Speaking & faculty fees$183,26574%
- Grants$1230%
- Travel & lodging$11,9575%
- Food & beverage$4,7992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 184 | $203,800 |
| Boston Scientific | 25 | $25,491 |
| Edwards Lifesciences | 20 | $15,750 |
| Abiomed | 2 | $3,010 |
| Abbott | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$138,852
- CoreValve Evolut$61,761
- GENERAL VASCULAR ACCESS$13,600
- GENERAL - THERAPIES$9,308
- Impella$3,000
- NAVITOR$150
- 3F$123
- APOLLOTM$108
How this compares
$248,201 in reported general payments places this provider in the 95th percentile of 27 cardiovascular disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 24 | $21,886 |
| Praluent PenAlirocumab | 11 | $5,213 |
| Atorvastatin Calcium | 75 | $967 |
| Metoprolol Succinate | 28 | $798 |
| Ezetimibe | 12 | $351 |
| Losartan Potassium | 29 | $310 |
| Carvedilol | 15 | $178 |
| ClopidogrelClopidogrel Bisulfate | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Burlington
- Daniel LustgartenBurlington$171K
- Shubash AdhikariBurlington$59K
- Adipong BrickshawanaBurlington$37K
- Thomas GillilandBurlington$35K
- Benjamin IrvineBurlington$11K
- David SchneiderBurlington$7K
- Ahmed HarhashBurlington$6K
- Sharan SharmaBurlington$4K
- Trace BarrettBurlington$4K
- Sherrie KhadangaBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.